A
Aileron Therapeutics
Clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases
About Aileron Therapeutics
Aileron Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines aimed at improving the outcomes and quality of life for cancer patients. The company operates in the biopharmaceutical market, specifically targeting historically undruggable targets with its proprietary platform of stabilized cell-permeating peptides. Aileron's lead product candidate, ALRN-6924, is designed to mimic the p53 tumor suppressor protein, disrupting its interactions with endogenous inhibitors to protect healthy cells during chemotherapy. This approach aims to prevent severe toxicities caused by off-target effects of cancer treatments.
Read full description
Aileron Therapeutics serves cancer patients undergoing chemotherapy, particularly those with small cell lung cancer (SCLC). The company generates revenue through the development and potential commercialization of its drug candidates, as well as through public offerings of its common stock.
At a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- Cambridge, United States
- Listing
- IPO 2017
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 75.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, Woman Founder, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Oct 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Aileron Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2026 | $58M | — | Ikarian Capital LLC · ADAR1 Capital Management · Cable Car Capital · Bios Partners | ↗ |
| POST IPO EQUITYOther financing | Jul 2025 | $15M | — | Yorkville Advisors | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$15M | — |
| 2025 | $0 | — | −$15M | — |
| 2024 | $0 | — | −$15M | — |
| 2023 | $0 | — | −$15M | — |
| 2022 | $0 | — | −$27M | — |
| 2021 | $0 | — | −$27M | — |
| 2020 | $0 | — | −$20M | — |
Growth signals
Latest recorded traffic for Aileron Therapeutics is 2.7K monthly website visits, up 12.5% over the last three months. Aileron Therapeutics's team declined 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Novartis Venture Fund
Apple Tree Partners
Series B and later16 investors entered at this stage
SR One
Excel Venture Management
Lilly Ventures
Roche Venture Fund
Aju IB Investment
Lincoln Park Capital Fund
BVF Partners- SMSatter Investment Management
Acorn Bioventures
Yorkville Advisors
Ikarian Capital LLC
ADAR1 Capital Management
Cable Car Capital
Bios Partners- SMStonepine Capital Management
Second Line Capital
Other known investors3 additional known investors
Dana-Farber Cancer Institute
Harvard University
Lung Therapeutics
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aileron Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aileron Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.